The Biogerontology Research Foundation was the first entity to produce comprehensive Longevity Industry Landscape Overviews in coordination with its strategic partner, Aging Analytics Agency. While the majority of its industry analytical resources have since been taken over by Aging Analytics Agency, the BGRF was pivotal to the initial development of those analytical frameworks.
Now in its 11th year of operations, the Biogerontology Research Foundation has been on the frontlines of developing the Longevity Industry to scale since its very inception.
Dmitry Kaminskiy, Managing Trustee of the Biogerontology Research Foundation, boldly predicted in 2014 that the Longevity Industry would see an inflection point in its development in 2017, becoming a recognized industry in the eyes of conservative investors, business analysts and top business media. This was at a time when investors and geroscientists alike were highly skeptical of the industry’s emergence within the next decade.
This prediction turned out to be true. 2017 witnessed an unprecedented rise in the number of Longevity-focused companies and investment deals, the emergence of half a dozen of geroscience-focused VC firms, coupled with widespread coverage of Longevity as a topic by mainstream media including The Economist, Financial Times and Bloomberg.
The Biogerontology Research Foundation has been on the forefront of advocating for and facilitating the paradigm shift from treatment to prevention since its inception, pushing the Longevity Industry away from ineffective reactionary single-disease treatments towards personalized, preventive and precision care. The foundation is pleased to see a large number of developments in this area over the past several years, and to see the paradigm of preventive medicine being embraced by progressive healthcare systems across the globe.
The Biogerontology Research Foundation has also been active in the shift from Precision Medicine to Precision Health through its many activities in the spheres of AI for ageing research and the development of practical, actionable biomarkers of ageing, urging the UK to focus on the intensive application of AI to preventive medicine and personalized care, utilizing the latest innovations in AI, Longevity, Biomarkers of Ageing and Advanced Biomedicine to become nation leading the world in the optimization of national health and an extension of national Healthy Longevity (Health-Adjusted Life Expectancy).